GEN-602-CT-101, NCT03775525: Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer |
|
|
| Active, not recruiting | 1 | 127 | US | GZ17-6.02, Capecitabine, Xeloda | Genzada Pharmaceuticals USA, Inc., Translational Drug Development | Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma | 05/23 | 12/23 | | |
